QUOTE AND NEWS
Motley Fool  Feb 10  Comment 
Here's how Regeneron Pharmaceuticals, Royal Dutch Shell, and United Parcel Service can get back to rewarding investors with gains.
newratings.com  Feb 10  Comment 
WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) disclosed in a regulatory filing on Thursday that in January 2017, the company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting...
MarketWatch  Feb 9  Comment 
Regeneron Pharmaceuticals Inc. said Thursday that it has been subpoenaed by the U.S. Attorney's Office over its support of a nonprofit that provides financial assistance to patients taking Regeneron medications. The subpoena, issued in January by...
Benzinga  Feb 9  Comment 
Canaccord Genuity said in a note released Wednesday the decision by a federal appeals court to stay the Praluent injunction in a patent litigation versus Amgen, Inc. (NASDAQ: AMGN) is a moderate positive for Regeneron Pharmaceuticals Inc ...
newratings.com  Feb 9  Comment 
PARIS (dpa-AFX) - Applied Genetic Technologies Corp. (AGTC) has a couple of catalysts coming its way this year. A phase I/II clinical trial of the company's XLRS product candidate for the treatment of X-Linked Retinoschisis has enrolled a...
newratings.com  Feb 9  Comment 
THOUSAND OAKS (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) and Sanofi announced that the United States Court of Appeals for the Federal Circuit has stayed the permanent injunction for Praluent (alirocumab) Injection pending the companies'...
Forbes  Feb 8  Comment 
Regeneron Pharmaceuticals is expected to report earnings of $3.09 per share on $1.30 billion in revenue. Meanwhile, the so-called Whisper number is $3.18. The Whisper number is the Street's unofficial view on earnings.
newratings.com  Feb 1  Comment 
PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that Health Canada approved Kevzara (sarilumab), an interleukin-6 (IL-6) receptor antibody, for the treatment of adult patients with moderately to severely active rheumatoid...




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki